Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Jan;136(1):138-48.
doi: 10.1053/j.gastro.2008.09.014. Epub 2008 Sep 18.

Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease

Anna S Lok  1 , Leonard B Seeff, Timothy R Morgan, Adrian M di Bisceglie, Richard K Sterling, Teresa M Curto, Gregory T Everson, Karen L Lindsay, William M Lee, Herbert L Bonkovsky, Jules L Dienstag, Marc G Ghany, Chihiro Morishima, Zachary D Goodman; HALT-C Trial Group
Collaborators, Affiliations

Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease

Anna S Lok et al. Gastroenterology. 2009 Jan.

Abstract

Background & aims: Although the incidence of hepatocellular carcinoma (HCC) is increasing in the United States, data from large prospective studies are limited. We evaluated the Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) cohort for the incidence of HCC and associated risk factors.

Methods: Hepatitis C virus-positive patients with bridging fibrosis or cirrhosis who did not respond to peginterferon and ribavirin were randomized to groups that were given maintenance peginterferon for 3.5 years or no treatment. HCC incidence was determined by Kaplan-Meier analysis, and baseline factors associated with HCC were analyzed by Cox regression.

Results: 1,005 patients (mean age, 50.2 years; 71% male; 72% white race) were studied; 59% had bridging fibrosis, and 41% had cirrhosis. During a median follow-up of 4.6 years (maximum, 6.7 years), HCC developed in 48 patients (4.8%). The cumulative 5-year HCC incidence was similar for peginterferon-treated patients and controls, 5.4% vs 5.0%, respectively (P= .78), and was higher among patients with cirrhosis than those with bridging fibrosis, 7.0% vs 4.1%, respectively (P= .08). HCC developed in 8 (17%) patients whose serial biopsy specimens showed only fibrosis. A multivariate analysis model comprising older age, black race, lower platelet count, higher alkaline phosphatase, esophageal varices, and smoking was developed to predict the risk of HCC.

Conclusions: We found that maintenance peginterferon did not reduce the incidence of HCC in the HALT-C cohort. Baseline clinical and laboratory features predicted risk for HCC. Additional studies are required to confirm our finding of HCC in patients with chronic hepatitis C and bridging fibrosis.

Trial registration: ClinicalTrials.gov NCT00006164.

PubMed Disclaimer

Conflict of interest statement

Potential investigator conflict of interest had been disclosed to study participants

Figures

Figure 1
Figure 1
Kaplan-Meier estimates of cumulative incidence of HCC (A) among patients randomized to maintenance peginterferon treatment or control and (B) among patients with bridging fibrosis (Ishak 3–4) vs. cirrhosis (Ishak 5–6) on baseline biopsy. Cases diagnosed within 12 months of enrollment were presumed to have been present at the time of enrollment and were excluded. One patient in the treatment group met criteria for HCC 11 months after randomization. This patient relapsed after 48 weeks of Lead-in treatment and had been in the study for 16 months at the time of randomization.
Figure 1
Figure 1
Kaplan-Meier estimates of cumulative incidence of HCC (A) among patients randomized to maintenance peginterferon treatment or control and (B) among patients with bridging fibrosis (Ishak 3–4) vs. cirrhosis (Ishak 5–6) on baseline biopsy. Cases diagnosed within 12 months of enrollment were presumed to have been present at the time of enrollment and were excluded. One patient in the treatment group met criteria for HCC 11 months after randomization. This patient relapsed after 48 weeks of Lead-in treatment and had been in the study for 16 months at the time of randomization.
Figure 2
Figure 2
Kaplan-Meier estimates of cumulative incidence of HCC among patients predicted to have low, intermediate, and high risk of HCC according to regression Model IV.
Figure 3
Figure 3
Kaplan-Meier estimates of cumulative incidence of HCC (A) in patients with and without esophageal varices or cirrhosis and (B) in patients with baseline platelet (plt) count <100, 100–149, and >150 × 1000/mm3
Figure 3
Figure 3
Kaplan-Meier estimates of cumulative incidence of HCC (A) in patients with and without esophageal varices or cirrhosis and (B) in patients with baseline platelet (plt) count <100, 100–149, and >150 × 1000/mm3
See this image and copyright information in PMC

Comment in

References

    1. Chen SL, Morgan TR. The natural history of hepatitis C virus (HCV) infection. Int J Med Sci. 2006;3(2):47–52. - PMC - PubMed
    1. Thomas DL, Seeff LB. Natural history of hepatitis C. Clin Liver Dis. 2005;9(3):383–98. vi. - PubMed
    1. Benvegnu L, Gios M, Boccato S, Alberti A. Natural history of compensated viral cirrhosis: a prospective study on the incidence and hierarchy of major complications. Gut. 2004;53(5):744–9. - PMC - PubMed
    1. Fattovich G, Giustina G, Degos F, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology. 1997;112(2):463–72. - PubMed
    1. Simonetti RG, Camma C, Fiorello F, et al. Hepatitis C virus infection as a risk factor for hepatocellular carcinoma in patients with cirrhosis. A case-control study. Ann Intern Med. 1992;116(2):97–102. - PubMed

Publication types

MeSH terms

Associated data